This is an interventional, randomized, crossover and double-blind placebo-controlled study.
The enrolled subjects will participate in two study sessions (V1 and V2, respectively) placed
at least one week apart.
A first screening visit (V0) is planned, during which the clinical-demographic data will be
collected, the patients will undergo a complete neurological and objective examination, and
an ECG will be performed to exclude major cardiac pathologies. Patients who meet the
inclusion / exclusion criteria will continue with the subsequent study sessions (V1 and V2).
During V1 and V2 the subjects must be in the inter-critical phase of the disease, i.e. free
from headache and in the absence of analgesic drugs in the previous 48 hours.
First study session (V1):
At baseline (T0), disease assessment scales (MIDAS, HIT-6, ASC-12, MSQ, BDI, STAI) will be
administered, and the first electrophysiological test session (nociceptive blink reflex -nBR)
will be performed along with the first blood sample from a peripheral venous catheter
positioned in the antecubital vein.
At the end of the baseline evaluation, the subjects will be randomized into two groups to
receive, during the first of the two sessions, NTG (0.5 μg / kg / min intravenous in 20
minutes) or placebo (intravenous saline in 20 minutes) via infusion pump.
The subjects will then be monitored in hospital for 4 hours following the NTG infusion
(hospital phase) and then discharged with the indication to keep a headache diary for a
further 8 hours (12 hours of overall observation). At the end of the 4 hours of hospital
observation, the investigator or the patient may decide to extend the observation period
based on the possible occurrence of adverse effects or in any case as required.
Starting from the infusion, the onset of headache and associated characteristics (nausea,
vomiting, photophobia, phonophobia, location of pain, quality of pain, aggravation with
cough, intensity) will be evaluated every ten minutes, as well as the presence of other
symptoms or adverse events. The vital parameters (blood pressure, heart rate) will be
monitored every 5 minutes during the infusion, then every 10 minutes for the entire duration
of the in-hospital observation. Additional vital sign measurements will be performed based on
clinical need or trend.
After 2 hours (T1) and 4 hours (T2) from the end of the NTG / placebo infusion, the
electrophysiological evaluations and blood samples will be repeated, and the assessment scale
for allodynia (ASC-12) will be administered.
In subjects in which the induced migraine attack will appear within the hospital observation
phase (4 hours), sumatriptan 6 mg will be administered subcutaneously. 1 hour after the
administration of sumatriptan, the electrophysiological evaluation of the nBR and blood
sampling after (TS) will be repeated.
Second study session (V2):
Patients will return to the center for the second session (V2) of the study at least one week
after the first session. The second session will completely mirror the first, patients will
receive placebo (intravenous saline in 20 minutes) or NTG (0.5 μg / kg / min intravenous in
20 minutes) in cross-over according to the randomization list.
It is specified that, for female subjects, a urine pregnancy test will be carried out before
each study session.
The patient will be informed that headache may arise during the test, but no information will
be shared on the possible course after NTG / placebo to avoid breaking the blind.
NBR registration procedure:
The R2 response of nBR will be evaluated using a planar concentric electrode (Bionen,
Florence, Italy), placed 10 mm above the emergence of the supraorbital nerve. For each
subject, the preferential side of pain localization of migraine crises will be chosen,
alternatively the right side will be used. Stimulation parameters: single monopolar
stimulation, duration 0.3 ms, band filter: 3 Hz to 3 kHz, recording frequency: 2.5 kHz,
analysis time: 200ms, sensitivity: 100 mV.
The surface electromyographic recording (CED Powerlab 1401, Cambridge Electronic Design) will
be carried out at the level of the orbicularis oculi muscle through a pair of surface
electrodes, the reference electrode on the side of the eye, the recording electrode on the
midpoint of the lower eyelid. A progressive increase in the stimulation intensity (0.3 mA at
a time) will be used to evaluate the reflex threshold (RT = reflex threshold), defined as a
stably present response to at least 3 stimulations. To assess the habituation of nBR, 26
consecutive stimuli will be administered at different stimulus frequencies, according to a
random order (0.2, 0.3, 0.5 Hz), with a stimulation intensity equal to 1.8 times the RT. Of
these stimulations, the first will be removed from the analysis to eliminate the startle
response. The 25 electromyographic recordings will be collected in 5 blocks, and the values
of the area under the amplitude curve (AUC, ms * mV) will be calculated for each block. The
percentage change in the AUC of the last block, compared to the first, represents the
"habituation index" (HI) value.
Biochemical panel:
Plasma levels of pro and anti inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-4,
IL-10) through a latest generation ELISA analysis
Plasma levels of quinolinic acid, through mass spectrometry;
Plasma levels of CGRP, PACAP, VIP through commercially available ELISA kits.
Gene expression of the cytokines mentioned above and specific microRNAs (mir-155,
mir-382, mir-34a, mir-30a) and MALAT1 through RT-PCR method.